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Abstract
Herpes simplex virus (HSV) entry into the cells requires glycoproteins gD, gH/gL and gB,
activated in a cascade fashion by conformational modifications induced by cognate recep-
tors and intermolecular signaling. The receptors are nectin1 and HVEM (Herpes virus entry
mediator) for gD, and αvβ6 or αvβ8 integrin for gH. In earlier work, insertion of a single chain
antibody (scFv) to the cancer receptor HER2 (human epidermal growth factor receptor 2) in
gD, or in gH, resulted in HSVs specifically retargeted to the HER2-positive cancer cells,
hence in highly specific non-attenuated oncolytic agents. Here, the scFv to HER2 was
inserted in gB (gBHER2). The insertion re-targeted the virus tropism to the HER2-positive
cancer cells. This was unexpected since gB is known to be a fusogenic glycoprotein, not a
tropism determinant. The gB-retargeted recombinant offered the possibility to investigate
how HER2 mediated entry. In contrast to wt-gB, the activation of the chimeric gBHER2 did
not require the activation of the gD and of gH/gL by their respective receptors. Furthermore,
a soluble form of HER2 could replace the membrane-bound HER2 in mediating virus entry,
hinting that HER2 acted by inducing conformational changes to the chimeric gB. This study
shows that (i) gB can be modified and become the major determinant of HSV tropism; (ii)
the chimeric gBHER2 bypasses the requirement for receptor-mediated activation of other
essential entry glycoproteins.
Author summary
Herpes simplex virus encodes an entry apparatus made of the glycoproteins gD, gH/gL
and gB. gD is the major determinant of HSV tropism. Receptor-induced modifications to
gD and gH/gL activate in a cascade fashion gB, the conserved fusogenic glycoprotein
across the Herpesviridae family. In herpesviruses other than HSV, but not in HSV, gB also
contributes to determine the virus tropism. We took advantage of retargeting studies to
investigate the process of HSV glycoprotein activation, and the specific roles played by the
glycoproteins. When a heterologous ligand is engineered in gB, the virus tropism is retar-
geted to the ligand receptor. gB becomes the major determinant of HSV tropism, and
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does not any longer need the receptor-mediated activation of glycoproteins gD and gH/
gL.
Introduction
Herpes simplex virus encodes a multipartite entry apparatus made of four essential glycopro-
teins, named gD, the heterodimer gH/gL and gB, with distinct functions [1–4]. gD, whose
structure includes an Ig-folded core with extensions, serves as a typical receptor-binding glyco-
protein, and the major determinant of HSV tropism [5–7]. The heterodimer gH/gL is a multi-
domain protein, with no structural resemblance to any known protein [8–10]. gB is a trimer
with structural features typical of viral fusion glycoproteins [11–13]. gH/gL and gB form the
conserved fusion apparatus across the Herpesviridae family. The quartet assembles in com-
plexes [14, 15, 16–18]. Contact regions among the glycoproteins were identified [10,17–20].
The system of receptors for the quartet of glycoproteins appears to be more and more complex,
and affects the process of glycoprotein activation at virus entry. gD interacts with three alterna-
tive receptors, nectin1, HVEM, and modified heparan sulphate [21–24]. gH/gL interact with
the αvβ subfamily of integrins [25,26]. αvβ6 and αvβ8 are required for entry, in that their
depletion, or block with antibodies, results in block to virus infection [26]. Three co-receptors
for gB were reported. They are PILRα (paired immunoglobulin-like type 2 receptor-alpha),
myelin associated glycoprotein, and isoforms IIA and IIB of non-muscle myosin heavy chain
[27–30]. Little is known about the role they play in HSV entry. In particular, there is no evi-
dence that they contribute to define the host range of the virus. PILRα was reported to be
expressed, and possibly to play a role in HSV infection of monocytes, a cell type not usually
targeted by HSV [27]. The effect, if any, of depleting this receptor in epithelial cells, the targets
of wt-HSV in vivo, was not investigated. The lack of contribution of gB receptors to overall
viral tropism is highlighted by the finding that abrogation of the gD interaction with one of its
receptors abrogates virus entry in virtually any cell.
The current model of HSV entry envisions that the four glycoproteins switch from an inac-
tive to a fusion-active conformation [2–4,31]. Although numerous steps in this model remain
to be elucidated, it is well documented that activation is triggered by the gD binding to one of
its alternative receptors, and then propagates to gH/gL, and finally to gB in a cascade fashion.
The conformational changes to gH/gL are induced upon transmission of a signal from recep-
tor-bound gD, and upon interaction with one of the two integrins, and was documented as
displacement of gL from the heterodimer [26,32]. The displacement only occurs if all the viral
and cellular components of the entry apparatus are present, and is prevented by a MAb to gH
with strong neutralizing activity, supporting the view that it is part of the process of gH activa-
tion [32].
The HSV glycoproteins are of interest in the design of oncolytic HSVs. Recently, this field
received much attention upon Federal Drug Administration and European Medicines Agency
approval of the oncolytic HSV, originally named OncovexGM-CSF, for the treatment of meta-
static melanoma [33,34]. For this virus, as well as numerous oncolytic viruses, cancer specific-
ity has been achieved at the expense of virulence [35,36]. In essence, they carry deletions or
mutations in genes involved in contrasting the innate response to the virus, and take advantage
of the fact that cancer cells mount a very weak response to them [37–39]. The drawback is that
these viruses are attenuated and may replicate poorly [37]. The strategy pursued by other labo-
ratories, including ours, is to develop non-attenuated oncolytic HSVs, by retargeting the HSV
tropism to cancer-specific receptors [40–42]. The initial studies identified gD as the
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glycoprotein to be modified in order to readdress virus tropism to a receptor of choice, and
detarget from the natural gD receptors [41]. In our studies, the selected receptor was HER2
(human epidermal growth factor receptor 2), a member of the EGFR (epidermal growth factor
receptor) family, overexpressed in about 25–30% of breast and ovary cancers, as well as in
stomach, lung and other cancers [43]. Retargeting was achieved by engineering in gD a single
chain antibody (scFv) to HER2, derived from trastuzumab, and by appropriate deletions in
gD, which remove critical residues for interaction with HVEM and nectin1 [44–47]. Recent
studies from our laboratory showed that also gH can be a tool for retargeting [48]. Thus, the
insertion of a scFv to HER2, combined with an appropriate deletion in gD, lead to a HSV fully
retargeted to HER2 through gH.
Here, we asked whether gB is a suitable glycoprotein for retargeting. We engineered the
scFv to HER2 between AA 43 and 44 of gB, thus generating R-903. By further deletion of AA
6–38 in gD, the recombinant could be detargeted from natural receptors. The retargeting to
HER2 via gB was unexpected, since gB is the fusogenic glycoprotein, and was not known to be
a determinant of HSV tropism. Inasmuch as the scFv to HER2 mediates entry when engi-
neered in gD, gH, or gB we asked how can a same ligand, engineered in one or the other of the
three glycoproteins—gD, gH or gB—enable entry through the HER2 receptor.
Results
Engineering of recombinants carrying scFv to HER2 in gB
The scFv to HER2 was engineered in gB between AA 43–44, thus generating R-903 (Fig 1A).
This position is known to accept the heterologous ligand green fluorescent protein (GFP) [49].
Fig 1. (A) Genome arrangement of recombinants R-903 and R-909. The HSV-1 genome is represented as a
line bracketed by repeats (R). The Lox-P-bracketed BAC sequence and eGFP fluorescent marker are inserted in
the intergenic region UL3-UL4. R-903 carries the insertion of scFv-HER2, with a downstream 12 Ser-Gly linker,
between AA 43–44 of gB. R-909 is the same as R-903; in addition, it carries the deletion of AA 6–38 from mature
gD for detargeting purpose. (B) R-909 expresses the chimeric gBHER2 glycoprotein. Lysates of SK-OV-3 cells
infected with R-909 (lane 1), or the wt R-LM5 (lane 2) (3 PFU/cell) were subjected to PAGE, and immunoreacted
with MAb H1817 to gB [53]. Lane 3 indicates uninfected SK-OV-3 cells. Arrows point to the migration position of
chimeric gBHER2 and of wt-gB. Figure to the left indicates the migration position of Mr markers, expressed in
kDaltons.
https://doi.org/10.1371/journal.ppat.1006352.g001
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The R-909 recombinant was derived from R-903 by deletion of AA 6–38 in gD, for detargeting
from the natural gD receptors, HVEM and nectin1 (Fig 1A) [45]. Both recombinants carry the
Lox-P bracketed BAC sequence and the eGFP (enhanced green fluorescent protein), cloned in
the intergenic UL3-UL4 region. The presence of the scFv insert was verified by sequencing the
ORF, and by sodium dodecyl sulphate-polyacrylamide gel elecctrophoresis (SDS-PAGE) and
immunoblotting. As expected, gB from R-909 exhibited a lower electrophoretic mobility than
wt-gB present in the R-LM5 recombinant (Fig 1 B). The latter recombinant carries the BAC
and eGFP sequences and is otherwise wt (see Fig 2 A for its tropism) [45].
R-903 and R-909 infect cells that express HER2 as the sole receptor,
use HER2 as portal of entry, and do not necessitate of a gD receptor
The modifications to tropism were assayed in J cells which transgenically express the receptor
of choice, HVEM, nectin1, or HER2. J cells are negative for HSV gD receptors and cannot be
infected by wt-HSV [21]. The cells were infected with R-903 and R-909 recombinants, and
scored by fluorescence microscopy. Fig 2A shows that R-903 and R-909 infected J-HER2 cells,
implying that they were retargeted to HER2. R-903 also infected J-HVEM and J-nectin1 cells,
as expected, given that it encodes a wt-gD. In contrast, R-909 failed to infect through the gD
receptors, in agreement with the AA 6–38 deletion in gD. The tropism of R-909 was essentially
similar to that of R-809 (previously named R-VG809), retargeted to HER2 by insertion of scFv
in gH, and detargeted from gD receptors [48]. As expected, the wt R-LM5 infected J-nectin1
and J-HVEM cells and failed to infect J-HER2 cells. For a summary of nomenclature and prop-
erties of viruses employed in this study, see Table 1. R-909 was further assayed for ability to
infect HER2-pos (SK-OV-3, BT-474, MDA-MB-453) and HER2-neg HeLa, MDA-MB-231
cancer cells, and the keratinocytic cell line HaCaT. The non-detargeted R-903 was included as
control. Fig 2B shows that R-909 infected the HER2-pos cells, but failed to infect the HER2-neg
cells. By contrast, R-903 infected both sets of cells. The results strengthen the conclusion that
R-909 is retargeted to HER2 via gB and detargeted from natural gD receptors.
Three main conclusions can be drawn from this set of experiments. First, the insertion of a
scFv in gB modifies HSV tropism. This was a surprising result since gB is known for its ability
to carry out virion-cell fusion, but not as determinant of HSV tropism. Second, the finding
that R-909 infected J-HER2 cells, but not J cells, suggests that the scFv in gB enabled gB activa-
tion upon interaction with HER2, and rules out that gB activation occurred independently of
the interaction with HER2. Lastly, the infection of J-HER2 cells with R-909 occurs in the
absence of a gD receptor, or with a deleted gD unable to bind its natural receptor. Essentially,
it is independent of receptor-mediated gD activation. These properties imply that the cascade
of glycoprotein activation that ultimately leads to gB activation does not occur in a canonical
manner in R-909, i.e. starting from receptor-bound gD and via transmission to gH/gL and
then to gB.
Replication and killing activity of R-909
Fundamental properties for any candidate oncolytic virus are the extent of replication and the
ability to kill the infected cells. SK-OV-3 cells were infected with R-909 at 0.1 PFU/cell. The
gH-retargeted R-809, the gD-retargeted R-LM113, and the wt HSV-1(F) were included for
comparison. Virus yields were determined at 0 time (3 h), 24 and 48 h after infection. Fig 3A
shows that R-909 grew to titers very similar to those of R-809, and less than one log lower than
those of the gD-retargeted R-LM113. All retargeted viruses replicated between 1–2 log less
than the parental HSV-1(F). Fig 3B shows that plaques from R-909 were bigger in size relative
to R-809 and R-LM113; all were smaller relative to R-LM5.
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The killing ability of R-909 for the HER2-pos MDA-MB-453 and SK-OV-3 cancer cells is
reported in Fig 3C–3E. Cytotoxicity of R-909 was very similar to that of R-809 and HSV-1(F),
especially at 7 days after infection, and ranged from 70 to 90% at 7 days after infection for the
HER2-positive SK-OV-3 and MDA-MB-453 cells. R-909 and R-809 failed to kill the HER2-neg
Fig 2. R-909 specifically infects HER2-pos cells. (A) Both the R-909 and the non-detargeted R-903 infect
cells that express HER2 as the sole receptor (J-HER2 cells). J cells express no receptor for wt-HSV. J-HER2,
J-nectin1 and J-HVEM express only the indicated receptor. The pattern of infection of R-909 is similar to that
of R-809, and differs from that of R-LM5. (B) R-909, but not R-903, specifically infects HER2-pos, and fails to
infect the HER2-neg cancer cells. In all panels, the indicated cells were infected at 3 PFU/cell. Infection was
monitored at 24 h by fluorescence microscopy.
https://doi.org/10.1371/journal.ppat.1006352.g002
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MDA-MB-231 cancer cells (Fig 3E), consistent with failure to infect them, whereas the wt
HSV-1(F) killed about 90% at 7 days after infection (Fig 3E). Cumulatively, the results show
that retargeting through gB confers very similar properties as retargeting through gH, in terms
of virus growth, plaque size and killing ability.
Table 1. Summary of genotypic modifications and tropism of recombinants.









R-903 gB none + - This
paper
R-909 gB gDΔ6–38 + + This
paper
R-809* gH gDΔ6–38 + + [48]
R-LM113 gD gDΔ6–38 + + [45]
R-LM249 gD gDΔ61–218 + + [46]
R-LM5 none none - - [45]
*, previously named R-VG809
https://doi.org/10.1371/journal.ppat.1006352.t001
Fig 3. Extent of R-909 replication in SK-OV-3 cells, plaque size and ability to kill cells. (A) SK-OV-3
cells were infected with R-909, with R-809, R-LM113, wt HSV-1(F), as controls, at 0.1 PFU/cell, and
harvested at the indicated times (h) after infection. Progeny virus was titrated in SK-OV-3 cells. (B) Relative
plaque size of R-909, and of R-809, R-LM113, wt R-LM5, as controls, in SK-OV-3 cells. Figures in brackets
represent the average size of 10 plaques, in pixels. (C-E) Killing ability of R-909, R-809 and HSV-1(F) for the
HER2-pos SK-OV-3 and MDA-MB-453 cells, and absence of killing ability for the HER2-neg MDA-MB-231
cancer cells. SK-OV-3 and MDA-MB-453 cells were infected at 2 PFU/cell and MDA-MB-231 cells were
infected with R-909 and R-809 at 0.1 PFU/cell. MDA-MB-231 cells were infected with wt HSV-1(F) at 0.05
PFU/cell. Cell viability was quantified by alamarBlue assay at the indicated days after infection. Results are
the average of at least two independent experiments, each of which carrying quadruplicate samples ± S.D.
https://doi.org/10.1371/journal.ppat.1006352.g003
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R-909 uses HER2 as portal of entry, and infection is inhibited by
neutralizing MAbs to gD, gH, gB
To verify that R-909 infection occurs through the interaction of the chimeric gB (gBHER2) with
HER2, we verified whether gBHER2 binds HER2, and whether R-909 infection was inhibited by
trastuzumab, the MAb to HER2 from which the scFv was derived [50]. For the binding assay,
we cloned gBHER2 from R-909, gHHER2 from R-803. 293T cells were transfected with gBHER2,
gHHER2, or their wt counterpart, and reacted with a soluble truncated form of HER2. Fig 4A
and 4C show that the chimeric gBHER2, and gHHER2 reacted with soluble HER2, whereas the wt-
gB and wt-gH did not. This result shows that the binding of gBHER2, or gHHER2 to HER2 occurs
in the absence of the other glycoproteins. For the infection assay, we infected J-HER2 or
Fig 4. gBHER2 and gHHER2 interact with a truncated soluble form of HER2, and infection of R-909 is
dependent on HER2 and is inhibited by antibodies to gD, gH/gL, gB. (A-D) DNA encoding wt gH/gL (D),
gHHER2/gL (C), wt gB (B) or gBHER2 (A), was transfected into 293T cells. 24 h later, cells were fixed with
paraformaldehyde, and then reacted with a truncated soluble form of HER2 (E) J-HER2 and SK-OV-3 cells were
infected with R-909, R-LM113, R-LM5. Cells were pretreated with trastuzumab (28 μg/ml) or control mouse IgGs
(28 μg/ml). Extent of infection was quantified 24 h later by flow cytometry, and expressed as percentage relative to
cells infected with or untreated cells. Each value represents the average of three independent experiments ± S.D.
(F-G) R-909, R-LM113, and the wt-R-LM5 were preincubated with MAbs HD1 to gD (low, 1.5 μg/ml; high, 30 μg/
ml), MAb 52S to gH/gL (ascites fluid 1:25), or MAb H126 to gB (ascites fluid 1:2000) for 1 h at 37˚C, and then
allowed to infect SK-OV-3 (F) or J-HER2 (G) cells. Extent of infection was quantified 24 h later by flow cytometry,
and expressed as percentage relative to cells infected with untreated virus. Each value represents the average of
three independent experiments ± S.D.
https://doi.org/10.1371/journal.ppat.1006352.g004
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SK-OV-3 cells in the presence of trastuzumab. A wt HSV was not included as it does not infect
J-HER2 cells (see Fig 2A and references [44] and [45]). Trastuzumab blocked entry of R-909
and R-LM113, but not of R-LM5 (Fig 4E), indicating that R-909 uses HER2 as a portal of entry.
This finding and the above implication that R-909 did not require the canonical cascade of
glycoprotein activation triggered by the gD interaction with nectin1 or HVEM prompted us to
further characterize the entry process of R-909. We asked whether R-909 infection was inhib-
ited by neutralizing antibodies to gD, gH and gB. R-LM113, and R-LM5 (see, Table 1) were
included for comparison. Virions were preincubated with MAbs to gD (HD1), to gH (52S), or
to gB (H126) [51–53]. All antibodies inhibited R-909 infection (Fig 4F and 4G); at low concen-
trations MAb HD1 failed to inhibit entry of R-909 and R-LM113, as noted earlier [48]. The
results indicate that infection with R-909 requires the essential glycoproteins gD, gH and gB.
Altogether, current and previous findings that HER2 can mediate HSV entry once the scFv
to HER2 is inserted in gD, in gH, or in gB, raise the question as to the mechanism by which
HER2 mediates entry of the three sets of recombinants. Subsequent experiments were finalized
to address this question, and were conducted by comparing R-909 to the gH-retargeted R-809
and to the gD-retargeted R-LM113 and R-LM249.
Role of gD in the cell-cell fusion mediated by retargeted gB and by
retargeted gH
The requirement for gD in infection of R-909 is in apparent contrast with the lack of require-
ment for receptor-mediated gD activation seen in J-HER2 cells, and may reflect multiple func-
tions of this glycoprotein. Evidence in favour of receptor-independent gD activities in virus
infection and cell-cell fusion was provided [42,54,55]. In particular, in addition to the trigger-
ing role exerted by receptor-bound gD, gD may play a “structural” role [48]. Inasmuch as the
entry glycoproteins assemble in complexes also in the absence of gD receptors [14–18], the
complete absence of anyone of the glycoproteins, or their binding to antibodies, may affect the
stability/structure/stoichiometry/gymnastics of the complexes [48]. A variety of techniques
were employed for detection of the complexes. Often, it was unclear whether the complexes
under study were or not fusion-competent, and/or whether they reflected functional com-
plexes in the virion envelope. A surrogate functional technique to infection has been the exten-
sively used cell-cell fusion assay. A key problem in interpreting the results of this assay is that it
is not known whether mutant glycoproteins, or specific mixtures, which exhibit a low level
activity in the cell-cell fusion, would give rise to infectious or non-infectious viruses. Thus, a
very low level of cell-cell fusion (about 4% of the fusion obtained with wt-glycoproteins) was
detected in the absence of gD with a partially deleted form of gH, which was interpreted as a
partially activated form of gH [56]. Virions carrying such deleted form of gH were not gener-
ated. In contrast to gH, virions carrying hyperactive forms of gB in the presence of gD, exhib-
ited no infection in the absence of gD [42]. All in all, a non-triggering, structural role of gD is
plausible, but has not been clearly documented so far. The HER2-retargeted gH (gHHER2) and
gB (gBHER2) offered the opportunity to dissect these two functions of gD. We set up a cell-cell
fusion assay, whereby the donor cells express the glycoproteins and T7 Polymerase, and the
target cells express the receptor—HER2 or nectin1—along with T7 promoter driven luciferase.
gBHER2 was cloned from R-909, and the gHHER2 was cloned from R-803. To mimic the situa-
tion in R-909 and R-809 recombinants, we also cloned gDΔ6–38. These glycoproteins, or their
wt versions, were transfected in appropriate combinations. Fig 5A shows that glycoprotein
mixtures which included the gBHER2 or gHHER2 promoted fusion with CHO-nectin1 cells in
the presence of wt-gD. These results imply that gBHER2 and gHHER2 maintain the fusogenic, or
pro-fusogenic, activity of their wt counterparts, although at somewhat reduced extent, in
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agreement with the infectivity of R-909 and R-809. Importantly, in the absence of gD, the
fusion activity dropped by at two-three logs and reached the background level (average value 5
x 10E3 relative luciferase units), suggesting that gD can not be omitted. Fig 5B shows that gly-
coprotein mixtures which included gBHER2, or gHHER2 exhibited a significant fusion activity
with CHO-HER2 cells, again somewhat lower than that of their wt counterparts with CHO-
nectin1 cells. wt-gB and wt-gH did not induce fusion with CHO-HER2 cells. The fusion activ-
ity with receptor-negative CHO cells was at the background level (Fig 5C). Thus, the cell-cell
fusion assay faithfully mirrored the pattern of infection of HER2-positive cells with R-909 or
R-809 virions. Of note, wt-gD could be replaced with gDΔ6–38, again mirroring the situation
with R-909 and R-809. However, no cell-cell fusion activity was detected in the total absence of
gD. Hence, although wt-gD, or gDΔ6–38, are not activated by HER2, and therefore do not play
a triggering activity, gD can not be omitted. The results provide experimental evidence in
favour of a role of gD other than triggering, most likely in favour of its structural role.
Entry pathway
Entry of HSVs into the cell occurs in a cell line dependent fashion by fusion at plasma mem-
brane (or with neutral endosomes), or by endocytosis into acid endosomes [57–59]. αvβ3 and
αvβ6 integrins intervene as routing factors, and promote the endocytic pathway of entry
[26,60]. Thus, infection of J-nectin1 cells with wt-HSV occurs by fusion at plasma membrane,
and is not inhibited by bafilomycin A (BFLA) [60]. Infection of J-nectin1 cells overexpressing
αvβ3 or αvβ6 integrins is via acidic endosomes and inhibited by BFLA. Here, we investigated
the pathway of R-909, R-809, R-LM113 and R-LM249 infection of J-HER2 and SK-OV-3 cells.
The BFLA inhibition curve shows that infection of J-HER2 cells was decreased with all recom-
binants, except R-LM113 (Fig 6A). Inhibition of SK-OV-3 cell infection was essentially similar
(Fig 6B). In these cells, the entry of wt R-LM5 was not inhibited by BFLA. Even the infection
of J-nectin1 cells with R-LM5 was not inhibited by BFLA (Fig 6C), in agreement with earlier
work [58]. Altogether, HER2 promoted an acidic endosome pathway of entry for all
Fig 5. gD is required to promote cell-cell fusion by HER2-retargeted gBHER2 or gHHER2. (A-C) Donor CHO
cells were transfected with the indicated mixtures of the following glycoproteins: wt-gD (gDwt), gDΔ6–38 (gDΔ), wt-
gH (H), HER2-retargeted gH (HHER2), wt-gB (B), HER2-retargeted gB (BHER2), wt-gL (L) and T7 polymerase.
Target cells were transfected with nectin1 (A), HER2 (B), or no receptor (C) plus T7-driven luciferase. Extent of
fusion was expressed as relative luciferase units (R.L.U.). Each column represents the average of triplicate
samples ± S.D.
https://doi.org/10.1371/journal.ppat.1006352.g005
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recombinants, but not for R-LM113. This property is in agreement with promotion of endocy-
tosis by EGFR family members [61]. Why R-LM113 and R-LM249 behave differently is
unclear at present. The two viruses differ with respect to the site of scFv insertion, which is N-
terminal in R-LM113, and replaces the gD core in R-LM249.
Entry of R-909 does not require αvβ6 or αvβ8 integrins and does not
result in gL displacement from gH/gL heterodimer
Previously, our laboratory showed that αvβ6 or αvβ8 integrins serve as receptors for HSV entry,
bind gH and contribute to its activation [26,62]. Hence, αvβ6 or αvβ8 integrins are part of the
mechanism of HSV glycoprotein activation that starts with the receptor-bound gD. Here, we
tested whether infection with the retargeted viruses R-909, R-809, R-LM113, and R-LM249
requires αvβ6 or αvβ8-integrins. SK-OV-3 cells (which express nectin1, αvβ3, αvβ6 and αvβ8
integrins) were simultaneously depleted of β6 and β8 subunits, or mock depleted (Fig 7A), and
then infected. As controls, we used the wt R-LM5. Extent of infection was monitored through
eGFP or mCherry. The results summarized in Fig 7B show that infection with R-909 was unaf-
fected by β6 and β8 integrins depletion. By contrast, infection with the wt R-LM5 was almost
Fig 6. Endocytic entry of R-909 into J-HER2 and SK-OV-3 cells. (A-C) J-HER2 (A), SK-OV-3 (B), or J-
nectin1 (C) cells were infected with the indicated viruses, in the presence of increasing nM concentrations of
Bafilomycin A (BFLA). The extent of infection of GFP-positive viruses was determined by GloMax Discover
System (Promega), and that of R-809 was determined by FACS. Each point represents the average of
triplicate samples ± S.D.
https://doi.org/10.1371/journal.ppat.1006352.g006
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completely abolished. Infection with the gD-retargeted R-LM113 or R-LM249 was decreased
but not abolished in the depleted cells. Interestingly, also the infection with the gH-retargeted
R-809 was not decreased by the β-integrins depletion. Thus, the recombinants retargeted
through gB, or through gH, exhibited null-to-low requirement for β6 or β8 integrins. In con-
trast, the wt virus and the gD-retargeted virus exhibited a very high, or high requirement for β6
and β8-integrins. In brief, there appears to be a gradient in terms of integrins-dependence going
from wt- and gD-retargeted, to gH-retargeted and to gB-retargeted recombinants.
The ligand to αvβ6 or αvβ8 integrins is gH/gL [26]. Earlier, we showed that integrins induce
a conformational change to gH/gL, that results in the displacement of gL from the heterodimer
[32]. The displacement occurs at virus attachment/entry, and is prevented under conditions
that block virus entry. It only occurs if all the components of the entry apparatus are present, in
particular it requires receptor-activated gD as well as gB. Several lines of evidence indicated that
it is most likely part of the activation process of gH/gL [32]. The gL displacement can be readily
monitored in cell overexpressing αvβ6 integrin, by comparing the reactivity of virions to two
anti-gH MAbs. MAb 52S recognizes a gL-independent epitope, and reflects the total quantity of
virions absorbed to cells. MAb 53S recognizes a gH epitope that is formed only when gH hetero-
dimerizes with gL (gL-dependent gH epitope) [52]. Once virions attach to cells, the gL displace-
ment is detected as a decrease in MAb 53S reactivity, relative to MAb 52S reactivity [32]. Here,
Fig 7. Inhibition of infection in cells depleted of β6 and β8 integrins. (A) Extent of integrins silencing.
SK-OV-3 cells were doubly silenced for β6 and β8 integrins (siRNA β6+β8), or mock-silenced (siRNA ctrl).
Extent of silencing was measured by qRT-PCR, and expressed as fold decrease relative to siRNA ctrl cells.
Each column represents the average of triplicates from two independent experiments ± S.D. (B) Effect of
integrins silencing on infection. SK-OV-3 cells silenced with siRNA ctrl, or siRNA β6+β8, were infected with wt
R-LM5, R-LM113, R-LM249, R-809 and R-909 (5 PFU/cell), and harvested 24 h later. The extent of infection
was quantified by flow cytometry. Each point represents the average of triplicates. Bars show S.D.
https://doi.org/10.1371/journal.ppat.1006352.g007
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we asked whether the HER2-mediated entry of R-909 entails gL displacement, hence gH activa-
tion. J-HER2 or J-HER2 cells expressing αvβ6 integrin (J-HER2+αvβ6) were exposed to R-909
and, for comparison, to R-LM113, R-LM249 and R-809. Fig 8A shows that:
• attachment/entry of R-909 to J-HER2 or J-HER2+αvβ6 cells did not result in a decrease in
53S reactivity relative to 52S reactivity, irrespective of the overexpression of αvβ6 integrin.
• By contrast, attachment/entry of R-LM113 and R-LM249 to J-HER2+αvβ6, but not to
J-HER2 cells resulted in a sharp decrease in 53S reactivity, as previously observed for the wt-
HSV, herein exemplified by R-LM5.
Fig 8. Immunoreactivity of cells carrying absorbed virions to MAbs 52S and 53S to gH, and release of
gL in medium. (A) Partially purified virion preparations of wt R-LM5, R-LM113, R-LM249, R-809 and R-909
were absorbed for 30 min at 37˚C to J cells expressing nectin1 + αvβ6-integrin (nectin1+αvβ6), HER2 +
αvβ6-integrin (HER2+αvβ6), nectin1 alone (nectin1), or HER2 alone (HER2). Cells carrying absorbed virions
were then reacted with MAbs 52S (yellow) or 53S (pink) and analyzed by FACS. The percentage of FACS
positive cells to each MAb was determined. (B) Release of gL in medium. Immunoreactivity of the media
harvested after the 30 min virus absorption to cells (same samples as in A) to PAb gH/gL, MAb gB, and MAb
gD. The lanes to the left marked as R-LM5 show the electrophoretic mobility of the indicated HSV glycoproteins.
https://doi.org/10.1371/journal.ppat.1006352.g008
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• Attachment/entry of the gH-retargeted R-809 did result in decrease in 53S reactivity; how-
ever, this decrease took place independently of whether αvβ6 was present or absent; hence, it
was induced by HER2 and not by integrin.
In the samples where the 53S reactivity was decreased, there was a concomitant release of
gL in the medium (Fig 8B). We conclude the following.
• The gL displacement mediated by αvβ6 integrin takes place with R-LM113 and R-LM249; in
this case, in contrast to the wt-virus, the gD-activation is mediated by HER2 and not by
nectin1.
• The gL displacement takes place with R-809; in this case it is independent of αvβ6-integrin,
and is mediated by HER2, which directly targets gH.
• The gL displacement does not take place in R-909, either in the absence or in the presence of
αvβ6 integrin. The data argue that attachment/entry of R-909 is independent of β-integrins,
does not lead to gL displacement, and therefore the integrin-mediated gH activation does
not appear to be a critical step.
A soluble form of HER2 replaces the membrane-bound HER2 and
mediates R-909 infection
In a simplistic view, a receptor can mediate virus entry by promoting juxtaposition of the cell
and virion membranes. Alternatively, the receptor induces conformational changes and pro-
motes activation of the cognate glycoprotein. Experimentally, the two mechanisms can be dif-
ferentiated since, in the latter, but not in the former case, a soluble form of the receptor (or of
the glycoprotein), can substitute for the membrane-form of the receptor (or of the glycopro-
tein) [63,64]. The results described in the preceding paragraph hint that HER2 is capable to
activate the scFv-gB and scFv-gH chimeras of R-909, and R-809. To verify this further, we
asked whether entry of R-909, and R-809, can be mediated by a soluble form of HER2. The
receptor-negative J cells were exposed to R-909, R-809, R-LM113 R-LM249 and R-LM5
recombinants in the presence of a soluble form of HER2, or of BSA or soluble nectin1, as con-
trols. Twenty-four h later, cultures were scored by fluorescence microscopy, and the number
of fluorescent cells was quantified by FACS. The results of a typical experiment are shown in
Fig 9A–9O; the quantification is reported as histogram in Fig 9P, in which the lanes are named
with the same letters as the corresponding A-O panels. Soluble HER2 promoted entry of all
three sets of recombinants, R-909 (panel N), R-809 (panel K), and R-LM113 and R-LM249
(panels E, H). Soluble nectin1 mediated entry of R-LM5 (panel A), as expected. Infection was
negligible for all retargeted viruses in the absence of soluble HER2 (panels D, G, J, M), or in
the presence of BSA (panels F, I, L, O). The results clearly indicate that the soluble HER2 was
able to promote infection of all HER2-retargeted recombinants, and favour the view that
HER2 acts by promoting conformational modifications to the respective HER2-retargeted
glycoproteins.
Discussion
In this study we addressed the question whether gB is a suitable glycoprotein for HSV retarget-
ing. The aim was twofold, i.e., to better understand the biology of HSV entry through the les-
son of retargeting studies, and to expand and improve the toolkit for the design of retargeted
oncolytic HSVs. We report on three findings. First, the insertion of a scFv to HER2 in gB re-
addresses HSV tropism to the HER2 receptor. In essence, when gB carries a ligand, the ligand
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Fig 9. Virus entry mediated by a soluble HER2. (A-O) Receptor-negative J cells were exposed to R-LM5
(A-C), R-LM113 (D-F), R-LM249 (G-I), R-809 (J-L), and R-909 (M-O) for 3 h at 37˚C. Soluble form of HER2
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receptor contributes to define the host range of the virus. This was an unexpected result since
gB is responsible to execute the virion-cell fusion in HSV and across the Herpesviridae family.
Second, we asked how does the novel HER2 receptor enable entry of the recombinant carrying
the HER2-retargeted gB. We deleted a portion of gD, so that the virus lost the ability to use and
be activated by the natural gD receptors; we further depleted cells of β6 and β8 integrins, which
activate gH. We found that the entry of the gB-retargeted recombinant occurred in the absence
of the cascade of gD and gH activation. Third, retargeting through the chimeric gBHER2 was
intriguing since, the same scFv ligand to HER2 mediates entry when engineered in gD [45,46],
gH [48], or gB (this work). This raised the question of how can the same receptor—HER2—
enable virus entry by targeting alternatively gD, gH or gB, despite the fact that these glycopro-
teins carry out specific, non-interchangeable functions in wt-virus. We discuss these issues
separately.
gB is an effective tool for HSV tropism retargeting
R-909 is highly specific for HER2-positive cells. It replicated to similar yields as the gD-retar-
geted R-LM113 and the gH-retargeted R-809. It effectively killed HER2-positive cancer cells.
gB expands and improves the toolkit for the design of retargeted oncolytic HSVs. It can be
envisioned that retargeting via gB could be combined with retargeting via gD, or via gH, so as
to generate oncolytic HSVs capable to target cancer cells heterogeneous in receptor display.
Why retargeting via gB was unexpected
gB is the fusogenic glycoprotein in HSV and across the Herpesviridae family. The crystal struc-
ture of the post-fusion conformation showed features typical of fusion glycoproteins. gB is a
trimer, with a central coiled coil, and a crown that carries binding sites for major neutralizing
antibodies [11]. Each monomer carries a bipartite fusion loop. A closely similar structure is
exhibited by gB from Epstein Barr virus and human cytomegalovirus, hence the structure is
conserved across the Herpesviridae family [12,65]. The crystals were obtained for gB alone; no
co-crystal of gB with cellular proteins was reported. The structure of the prefusion conforma-
tion was inferred recently by electron cryotomography [66].
So far, gB was not recognized to be a determinant of HSV tropism. HSV gB interacts with
three receptors, PILRα, myelin associated glycoprotein, and non-muscle myosin heavy chain
IIA and IIB [27–30]. However, the role played by these receptors in HSV entry, including their
contribution to the host range of the virus, is poorly understood. Whether the receptors induce
conformational changes to gB, and contribute to gB activation is also unknown. It was noted
that the PILRα-mediated entry necessitates of gD [27].
R-909 entry occurs in the absence of receptor-mediated activation of gD
and gH
Two series of experiments support this contention. First, R-909 carries the deletion of AA
6–38 in gD, which ablates its ability to interact with, and be activated by nectin1/HVEM.
Hence, R-909 infection occurs in the absence of a nectin1/HVEM-mediated gD activation.
Second, infection of R-909, but not of wt-virus, occurred in cells depleted of β6 and
(S-HER2) (150 nM) (B, E, H, K, N), nectin1 (S-Nectin1) (150 nM) (A, D, G, J, M), or bovine serum albumin
(BSA) (150 nM) (C, F, I, L, O) were added to virion/cell mixtures for additional 3 h. 24 h later, micrographs
were taken at fluorescence microscope; in a replicate sample, cells were then trypsinized, and the number of
fluorescent cells was determined by flow cytometry (figures at the right-hand corner in each panel). (P) The
number of infected cells determined by FACS in panels A-O is shown as a histogram.
https://doi.org/10.1371/journal.ppat.1006352.g009
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β8-integrins [26]. At attachment/entry of R-909, the displacement of gL from gH/gL did not
take place. For wt-HSV, gL displacement appears to be part of the process of gH activation
[32]. We conclude that R-909 infection occurs in the absence of integrins-mediated gH activa-
tion. Altogether, whereas entry of the wt-virus requires the activation of gD and of gH by their
respective receptors in a cascade fashion, entry of the gB-retargeted virus does not. HER2
directly activates the chimeric gB. We conclude that the chimeric gB carries two functional
domains: the scFv that enables gB activation upon binding to HER2, and the fusogenic
domain, intrinsic to the glycoprotein.
With respect to gD, earlier and current work hinted that gD may encode activities other
than triggering of glycoprotein activation upon receptor binding [42,48,54,55]. We reasoned
that, since the entry glycoproteins assemble in complexes [14–17], even in resting virions [17],
the complete absence of anyone of the glycoproteins, or their binding to high amounts of anti-
bodies, may compromise the stability/structure/stoichiometry/gymnastics of the complex,
independently of their role in the cascade of activation. We refer to this as a “structural” role of
the glycoproteins [48], and searched evidence for it in a cell-cell fusion assay. The gBHER2, or
the gHHE2, or their wt counterparts, were transfected in combination with other components
of the fusogenic quartet (gD, gH, gL, gB). The transfected cells were allowed to fuse with target
cells expressing HER2 or nectin1. In all combinations the fusion by HER2-retargeted gB,
HER2-retargeted gH, or their wt counterparts required gD, be it wt or the non-activable gDΔ6–
38. This provides formal evidence for gD activity other than triggering, most likely for a struc-
tural role.
How can the same receptor—HER2—enable entry by targeting
alternatively gD, gH, or gB?
To shed further light on the mechanism of HER2-mediated entry, we compared three sets of
recombinants: the gD-retargeted R-LM113 and R-LM249, the gH-retargeted R-809, and the
gB-retargeted R-909. For all three recombinants the soluble HER2 was able to replace the
membrane-bound HER2 in mediating entry. Thus, a common feature was that HER2 did not
serve the function of anchoring the viruses to the cell; rather it induced conformational modi-
fications to the respective targeted glycoprotein. Interestingly, HER2 exerted differential effects
on the entry apparatus of the three sets of recombinants. While the wt R-LM5 required nec-
tin1/HVEM for gD activation and integrin for gL displacement, the gD-retargeted viruses
required HER2 for gD activation, and integrins for gH activation and gL displacement (Fig
10). In the case of the gH-retargeted R-809, HER2 brought about both gH activation and gL
displacement; gD activation by nectin1/HVEM was not needed. In the case of the gB-retar-
geted R-909, neither the gD nor gH activation and gL displacement were needed (Fig 10).
HER2 directly activated gB: because of this direct activation, there was no need for integrins
and for gL release. Thus, the direct activation of the chimeric gBHER2 by HER2 bypassed the
need for activation by receptor-activated gD and gH.
Concluding remark
It is possible to engineer a chimeric gB which carries two topologically and functionally dis-
tinct domains: the scFv that enables gB activation upon binding to the HER2, and the fuso-
genic machine, intrinsic to the glycoprotein. The chimeric gB does not need the activation
signaling by receptor-bound gD and gH. Functionally, the entry machine of the recombinant
R-909 is a monopartite apparatus.
The question arises as to why herpesviruses evolved to have a multipartite entry system.
The advantages of a multipartite entry system were in part addressed in a recent review (see,
Retargeted HSV gB bypasses upstream activation
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006352 April 19, 2017 16 / 25
[62]). Briefly, HSV needs specific integrins in order to promote endocytosis, the preferred
route of entry for HSV and for other herpesviruses [26,60,67]. For most of the retargeted
HSVs, this role appears to be carried out by HER2, which promoted the endocytic pathway of
entry. In addition, the multipartite system allows the virus to synchronize endocytosis with the
cascade of activation of the glycoproteins, so as to avoid premature activation, and exhaustion
of the entry apparatus [32,62]. Integrins activate a signalosome, which can be usurped to the
benefit of the virus. Across the family, the multipartite system may ensure a broad and diversi-
fied spectrum of receptors [62]. From an evolutionistic point of view, the monopartite system
may not ensure the level of sophistication granted to the family by the multipartite system.
Materials and methods
Cells and viruses
The J cells (negative for HSV receptors) and their derivatives expressing HER2, nectin1 or
HVEM were previously described [44,68]. J cells were in turn derived from baby hamster kid-
ney tk- (BHKtk-) cells (line B-1, GM0348A; National Institute of General Medical Sciences
Human Genetic Mutant Cell Repository, Bethesda, Md.), described in [69]. The R6 cell line is
a derivative of rabbit skin (RS) cells which expresses HSV gD in inducible manner, and can
complement HSV mutants in gD [70]. The RS cells were a generous gift from Prof. Bernard
Roizman (University of Chicago), who in turn received them from Dr. J. McLaren (University
of New Mexico) [71]. The above cells were grown in DMEM (#31600–083, Gibco Laborato-
ries) supplemented with 5% fetal bovine serum (FBS) (#10270–106—E.U.-approved, South
America origin, Gibco Laboratories). The CHO, MDA-MB-231, MDA-MB-453, BT-474,
SK-OV-3, HaCaT and HeLa cells were purchased from ATCC and cultured as recommended
by ATCC. F-12 (Ham) nutrient mixture medium (#BE12615F, Lonza Group Ltd.) (CHO
Fig 10. Schematic entry pathways of HER2-retargeted recombinants and of wt-HSV-1. (A) wt-HSV. HVEM, or nectin1-activated gD
activates gH/gL, which upon additionally activation by integrins releases gL, and likely transmits signal to gB. (B) gD-retargeted HSVs,
R-LM113 and R-LM249. The HER2-retargeted gD is activated by HER2 and not by nectin1/HVEM. gH activation by activated gD, release
of gL, and signal transmission to gB is as in wt-virus. (C) gH-retargeted R-809. The chimeric scFv-HER2-gH is activated directly by
HER2, and not by gD, nor by integrins. gL is released. HER2-activated gH signals to gB. (D) gB-retargeted R-909. The chimeric scFv-
HER2-gB is activated directly by HER2, and not by gD, gH, and integrins. gL is not released.
https://doi.org/10.1371/journal.ppat.1006352.g010
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cells), Dulbecco’s modified Eagle medium (#31600–083, Gibco Laboratories), RPMI 1640-Glu-
tamax (#61870010, Gibco Laboratories) and FBS (#10270–106) were supplied by Lonza Group
Ltd. or GIBCO Laboratories (Life Technologies, Milano) as specified. The HSV-1(F) received
from Dr. B. Roiman was the prototype wt virus [72]. The recombinant viruses R-LM5,
R-LM113, R-LM249, R-803 and R-809 were described elsewhere [45,46,48].
Antibodies and soluble receptors
R8 polyclonal antibody (PAb) to gD and BD80 monoclonal antibody (MAb) to gD were gener-
ously provided by Dr. G. H. Cohen and Dr. R. Eisenberg. MAbs HD1 and H126 were a gift
from Dr. L. Pereira. MAb H1817 was purchased from Goodwin Institute. MAbs 52S and 53S
were described [52]. A PAb to gH/gL was derived to a soluble form of gH truncated at aa 789/
gL produced in insect cells [17]. Recombinant human ErbB2/HER2 Fc chimera corresponding
to soluble form of HER2 (S-HER2) was purchased from R&D System. Soluble form nectin1
(S-Nectin1) was described [68]. Bovine serum albumin (BSA) was purchased from Sigma-
Aldrich.
Engineering of HSV recombinants expressing genetically modified gBs
First, we engineered R-903 by insertion of the sequence encoding the trastuzumab scFv between
AA 43 and 44 of immature gB, corresponding to AA 13 and 14 of mature gB, after cleavage of
the signal sequence, which encompasses AA 1–30. The starting genome was the BAC LM5 BG,
which carries LOX-P-bracketed pBeloBAC11 and eGFP sequences inserted between UL3 and
UL4 of HSV-1 genome [45]. The engineering was performed by galK recombineering. Briefly,
the galK cassette with homology arms to gB was amplified by means of primers gB43GalKfor
GGTGGCGTCGGCGGCTCCGAGTTCCCCCGGCACGCCTGGGGT CGCGGCCGCGCCT
GTTGACAATTAATCATCGGCA and gB43GalKrev GGCCAGGGGCGGGCGGCGCCGG
AGTGGCAGGTCCCCCGTTCGCCGCCTGGGTTCAGCACTGTCCTGCTCCTT using
pGalK as template. This cassette was electroporated in SW102 bacteria carrying LM55 BG BAC.
The recombinant clones carrying the galK cassette were selected on plates containing M63
medium (15 mM (NH4)2SO4, 100 mM KH2PO4, 1.8 μg FeSO4H2O, adjusted to pH7) supple-
mented with 1 mg/L D-biotin, 0,2% galactose, 45 mg/L L-leucine, 1 mM MgSO47H2O and
12 μg/ml chloramphenicol. In order to exclude galK false positive bacterial colonies, the positive
recombinant clones were streaked also on MacConkey agar base plates supplemented with 1%
galactose and 12 μg/ml chloramphenicol and checked by colony PCR with primer galK_129_f
ACAATCTCTGTTTGCCAACGCATTTGG and galK_417_r CATTGCCGCTGATCACCA
TGTCCACGC. Next, the trastuzumab scFv cassette with the downstream Ser-Gly linker and
bracketed by homology arms to gB was amplified with primers gB43_sc4D5_for GGTGGCGTC
GGCGGCTCCGAGTTCCCCCGGCACGCCTGGGGTCGCGGCCGCGTCCGATATCCAGA
TGACCCAGTCCCCG and gB43_sc4D5_rev GGCCAGGGGCGGGCGGCGCCGGAGTGG
CAGGTCCCCCGTTCGCCGCCTGGGTACCGGATCCACCGGAACCAGAGCC using pSG-
scFvHER2-SG plasmid as template [48]. The recombinant genome encodes for the chimeric gB,
which carries the scFv to HER2 and one downstream Ser-Gly linker, with sequence SSGGGSGS
GGSG, and one linker between VL and VH region with the sequence SDMPMADPNRFRGKN
LVFHS. The recombinant clones carrying the excision of the galK cassette and the insertion
of the sequence of choice, scFv-HER2, were selected on plates containing M63 medium (see
above) supplemented with 1 mg/L D-biotin, 0.2% deoxy-2-galactose, 0.2% glycerol, 45 mg/L
L-leucine, 1 mM MgSO47H2O and 12 μg/ml chloramphenicol. Bacterial colonies were also
checked for the presence of sequence of choice by means of colony PCR with primers gB_ext_-
for GAGCGCCCCCGACGGCTGTATCG and gB_431_rev TTGAAGACCACCGCGATGC
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CCT. The starting material for R-909 was the R-903 BAC genome. To engineer the AA 6–38
deletion in gD, galK cassette flanked by homology arms to gD was amplified with primers
gD5_galK_f TTGTCGTCATAGTGGGCCTCCATGGGGTCCGCGGCAAATATGCCTTGG
CGCCTGTTGACAATTAATCATCGGCA and gD39_galK_r ATCGGGAGGCTGGGGGGCT
GGAACGGGTCCGGTAGGCCCGCCTGGATGTGTCAGCACTGTCCTGCTCCTT. Next,
we replaced galK sequence with a synthetic double-stranded oligonucleotide gD_aa5_39f
TTGTCGTCATAGTGGGCCTCCATGGGGTCCGCGGCAAATATGCCTTGGCGCACATC-
CAGGCGGGCCTACCGGACCCGTTCCAGCCCCCCAGCCTCCCGAT. To reconstitute the
recombinant virus R-903, 500 ng of BAC DNA was transfected into SK-OV-3 cells by means of
Lipofectamine 2000 (Life Technologies). Alternatively, for R-909, the corresponding BAC was
first transfected in gD-complementing cell line R6 (a rabbit skin cell derivative expressing glyco-
protein D under the control of HSV late promoter UL26.5) [70]. After one passage, the infected
cells were frozen. R-909 was subsequently grown and titrated in SK-OV-3 cells. Virus growth
was monitored by green fluorescence. The recombinants were genotyped by sequencing the gB,
gD and gH ORFs. To detect the expression of gBHER2, SK-OV-3 cells were infected at 3 PFU/
cell with R-909 and R-LM5, and harvested 72 h after infection. Cell lysates were subjected to
SDS-PAGE, transferred to polyvinylidene difluoride membranes and immunoblotted with
MAb H1817 to gB.
Infection of J cells expressing single receptors and of HER2+ and HER2-
cancer cells
The indicated J cell derivatives were infected with R-909, R-903, R-809 and R-LM5 at an input
multiplicity of infection of 3 PFU/cell for 90 min at 37˚C and monitored by fluorescence
microscopy 24 h post infection. The SK-OV-3, BT-474, MDA-MB-453 HER2-pos cancer cells,
and theHER2-neg HeLa and MDA-MB-231 cancer cells, and the HER2-neg non-cancer
HaCaT cells were infected at an input multiplicity of infection of 3 PFU/cell (as titrated in
SK-OV-3) for 90 min at 37˚C with R-909 and R-903. Pictures were taken 24 h after infection
by fluorescence microscopy.
Virus growth and plaque formation
SK-OV-3 cells were infected at 0.1 PFU/cell for 90 min at 37˚C. Unabsorbed virus was inacti-
vated by means of an acidic wash (40 mM citric acid, 10 mM KCl, 135 mM NaCl, pH 3). Repli-
cate cultures were frozen at the indicated times (3, 24 and 48 h) after infection and the progeny
was titrated in SK-OV-3. For plaque size determinations, the indicated viruses were plated
onto SK-OV-3 cells with agar overlay. Pictures of 10 plaques were taken for each virus. Plaque
areas (pxE2) were measured with Nis Elements-Imaging Software (Nikon). Each result repre-
sents average areas ± SD.
Cell viability assay
SK-OV-3, MDA-MB-453 and MDA-MB-231 cells were seeded in 96 well plates 8 x 103 cells/
well, and infected with the indicated viruses or mock-infected for 90 min at 37˚C. The input
multiplicity of infection (as titrated in the correspondent cell line) was 2 PFU/cell for the
SK-OV-3 and MDA-MB-453. MDA-MB-231 cells were infected with the recombinant viruses
R-909 and R-809 at approximately 0.1 PFU/cell (in these cells the viruses do not form plaques,
but only singly infected cells). MDA-MB-231 cells were infected with the wt HSV-1(F) at 0.05
PFU/cell. AlamarBlue (Life Technologies) was added to the culture media (10 μl/well) at the
indicated times after virus exposure and incubated for 4 h at 37˚C. Plates were read at 560 and
600 nm with GloMax Discover System (Promega). For each time point, cell viability was
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expressed as the percentage of AlamarBlue reduction in infected versus uninfected cells, after
subtraction of the background value (medium alone). Each point represents the average of at
least three triplicate samples ± SD.
Binding of chimeric glycoproteins to soluble form of HER2
100 ng of DNA encoding wt gH/gL, gHHER2/gL, wt gB or gBHER2 was transfected into 293T
cells by means of Lipofectamine 2000 (Life Technologies). 24 h later cells were fixed with para-
formaldehyde, incubated with a soluble truncated form of HER2 tagged with 6x His tag
(10 μg/ml, recombinant Human ErbB2/Her2 Fc chimera, R&D SYSTEM), subsequently incu-
bated with mouse anti-His antibody (1 μg/ml, Sigma-Aldrich), and with Anti-Mouse IgG (Fc
specific)-Alkaline Phosphatase (1:3000, Sigma-Aldrich) in presence of BCIP (5-bromo-
4-chloro-3-indolyl-phosphate, 166 μg/ml, Sigma-Aldrich) and NBT (nitro blue tetrazolium,
333 μg/ml, Sigma-Aldrich) substrate.
Block of infection with MAbs to HER2, gB, gH or gD
Replicate monolayers of J-HER2 cells, or SK-OV-3 cells in 12-well plates were preincubated
with trastuzumab, the MAb to HER2 from which the scFv-HER2 was derived or with non–
immune mouse IgG (28 μg/ml final concentration). After 1 h at 37˚C, the cells were infected at
an input multiplicity of infection of 5 PFU/cell (as titrated in SK-OV-3) with R-909 and
R-LM113 or R-LM5. Alternatively, where indicated, virions were pre-incubated with MAb
HD1 to gD (1.5 μg/ml, or 30 μg/ml), MAb H126 to gB (ascites fluid, 1:2000), MAb 52S to gH
(ascites fluid 1:25) for 1 h at 37˚C, and then allowed to adsorb to cells for 90 min. In the case of
MAb HD1, the combination of HD1 plus trastuzumab was also tested. Viral inocula were then
removed, and cells were overlaid with medium containing the indicated antibodies. Infection
was quantified by fluorescent activated cell sorter (FACS).
Plasmids
Expression plasmids for wt-gD, gB, gH, and gL were described [73]. EGFR2Δ (named erb-2)
carries the extracellular domain and transmembrane (TM) sequences of rat HER-2/neu
(nucleotides 25 to 2096) (GenBank accession number NM_017003) and is deleted of the tyro-
sine kinase domain [74]. Plasmid pcagt7 contains the T7 RNA polymerase gene under control
of the CAG promoter, and the pt7emcluc plasmid expresses the firefly luciferase under the T7
promoter [75]. Plasmids encoding nectin1 and HER2 were described [21,76].
gBHER2, gHHER2, and gDΔ6–38 were PCR amplified from R-909 or R-803, and cloned into
pcDNA3.1(-) (Thermo Fisher Scientific), as follows. gBHER2 was amplified with primers
gB5_XbaIf CCCCGTAGTTCTAGAGGCACGACGGGCCCCCGTAGTCCCGCCATGC and
gBB_EcoRI_r ACAACAAACGAATTCGATGCACATGCGGTTTAACACCCGTGG, then
digested with XbaI and EcoRI (New England Laboratories). The 3498 bp XbaI/EcoRI fragment
was ligated into the XbaI/EcoRI MCS of pcDNA3.1(-). The gHHER2 was amplified with prim-
ers gH803_XbaI_f GGGACGGGGTCTAGAATGGGGAATGGTTTATGGTTCG and
gH803_NotI_r CCGAAGCCAGCGGCCGCTTATTCGCGTCTCCAAAAAAACGGG, then
digested with XbaI and NotI (New England Laboratories). The 3325 bp XbaI/NotI fragment
was ligated into XbaI/NotI MCS of pcDNA3.1(-). gDΔ6–38 was amplified with primers
gD_XbaI_f GTGGTGCGTTCTAGAATGGGGGGGGCTGCCGCCAGG and gD_NotI_r
CCATTAAGGGCGGCCGCCTAGTAAAACAAGGGCTGGTGCG, then digested with XbaI
and NotI (New England Laboratories). The 1093 bp XbaI/NotI fragment was ligated into
XbaI/NotI MCS of pcDNA3.1(-). Inserts were verified by sequencing and by immunofluores-
cence of the encoded glycoproteins in transfected cells.
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Cell-cell fusion assay
The luciferase-based cell-cell fusion assay was performed as described [77,78]. Donor CHO
cells were transfected with the indicated glycoprotein mixture, and the targeted CHO cells
with the indicated receptor, or no receptor. Detection was done by means of a luciferase assay
system (Promega). The total amount of transfected plasmid DNA was made equal by the addi-
tion of EGFR2Δ 2 plasmid. Each value represents the average of triplicate samples.
Inhibition of infection by Bafilomycin A
A 160 mM stock solution of Bafilomycin A (BFLA) (Sigma Aldrich) was prepared in dimethyl
sulfoxide, and further diluted in medium. Cells were exposed to BFLA for 1 h at 37˚C and then
infected with R-LM5, R-LM113, R-LM249, R-809 and R-909 (5 PFU/cell) for 90 min in the
presence of BFLA. The viral inoculum was removed and the cells were overlaid with medium
containing BFLA for 18 h. The extent of infection of R-809 and of the GFP-expressing viruses
was determined by FACS, or by GloMax Discover System (Promega), respectively.
Integrin silencing and RT-PCR
Integrins were silenced in SK-OV-3 cells by means of ON-TARGET plus, smart polls (Dhar-
macon), as previously described [26]. Control cells were transfected with siRNA to E.coli-
poliA_0054 [26]. Extent of silencing was determined by RT-PCR using TaqMan gene expres-
sion assay (Applied Biosystems).
Flow cytometry and analysis of media
J cells transfected with indicated receptors were exposed for 30 min at 37˚C to R-LM5,
R-LM113, R-LM249, R-809, and R-909 at 10 PFU/cell, fixed with 4% (wt/vol) paraformalde-
hyde and incubated with 53S or 52S MAbs and secondary antibody. At the end of virus
absorption, the culture medium was concentrated; devoid of serum IgGs by Protein A-Sephar-
ose and subjected to SDS/PAGE. Immunoblot was performed by means of PAb to gH/gL,
MAb H1817 to gB and MAb BD80 to gD.
Entry mediated by soluble form of HER2
The receptor-negative J cells were exposed to R-LM5, R-LM113, R-LM249, R-809 and R-909
for 3 h at 37˚C. Soluble form of HER2 (150 nM) and bovine serum albumin (150 nM), used as
negative control, were added to cell-virions mixture for additional 3 h. As positive control, sol-
uble nectin1 (150 nM) was added to J cells exposed to R-LM5. 24 h later pictures were taken by
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